| WB | 咨询技术 | Human,Mouse,Rat |
| IF | 咨询技术 | Human,Mouse,Rat |
| IHC | 1/50-1/100 | Human,Mouse,Rat |
| ICC | 1/50-1/200 | Human,Mouse,Rat |
| FCM | 咨询技术 | Human,Mouse,Rat |
| Elisa | 1/10000 | Human,Mouse,Rat |
| Aliases | CD44; LHR; MDU2; MDU3; MIC4; CD44 antigen; CDw44; Epican; Extracellular matrix receptor III; ECMR-III; GP90 lymphocyte homing/adhesion receptor; HUTCH-I; Heparan sulfate proteoglycan; Hermes antigen; Hyaluronate receptor; Phagocytic glycopr |
| Entrez GeneID | 960 |
| WB Predicted band size | Calculated MW: 82 kDa; Observed MW: 90 kDa |
| Host/Isotype | Rabbit IgG |
| Antibody Type | Primary antibody |
| Storage | Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze/thaw cycles. |
| Species Reactivity | Human,Mouse,Rat |
| Immunogen | The antiserum was produced against synthesized peptide derived from human CD44. AA range:681-730 |
| Formulation | Purified antibody in PBS with 0.05% sodium azide,0.5%BSA and 50% glycerol. |
+ +
以下是3-4条关于CD44抗体的参考文献，涵盖不同研究方向和摘要内容：
1. **文献名称**：*CD44 antibody targeting in cancer therapy*
**作者**：P. Altevogt et al.
**摘要**：研究CD44抗体通过靶向肿瘤干细胞表面CD44受体，抑制肿瘤生长和转移的机制，并探讨其在乳腺癌和结肠癌模型中的应用。
2. **文献名称**：*Anti-CD44 monoclonal antibody enhances chemotherapy sensitivity in acute myeloid leukemia*
**作者**：L.C. Kim et al.
**摘要**：发现抗CD44单克隆抗体可阻断白血病细胞与微环境相互作用，增强传统化疗药物(如阿糖胞苷)的敏感性，减少耐药性。
3. **文献名称**：*CD44v6-specific antibody for targeted drug delivery in pancreatic cancer*
**作者**：R. Schmits et al.
**摘要**：开发针对CD44变异体v6的抗体-药物偶联物(ADC)，在胰腺癌模型中显著提高化疗药物靶向递送效率，并降低系统毒性。
4. **文献名称**：*CD44 blockade promotes anti-tumor immunity via macrophage reprogramming*
**作者**：C.R. Holmberg et al.
**摘要**：揭示抗CD44抗体通过重塑肿瘤相关巨噬细胞表型，增强T细胞浸润和免疫检查点抑制剂(如抗PD-1)的协同治疗效果。
这些研究展示了CD44抗体在靶向治疗、增敏化疗、药物递送及免疫调节中的多样化应用。
CD44 antibodies target a family of cell surface glycoproteins involved in cell-cell interactions, cell adhesion, and migration. CD44 is a transmembrane receptor for hyaluronic acid (HA) and other extracellular matrix components, playing key roles in immune response, inflammation, and cancer progression. It exists as multiple isoforms generated by alternative splicing, with the standard form (CD44s) expressed ubiquitously, while variant isoforms (CD44v) are tissue-specific and often upregulated in cancers.
CD44 is critical for lymphocyte homing, leukocyte activation, and stem cell maintenance. In cancer, its overexpression correlates with tumor metastasis, drug resistance, and cancer stem cell phenotypes, making it a therapeutic target. CD44 antibodies are widely used in research to study these processes, employing techniques like flow cytometry, immunohistochemistry, and functional blocking assays.
Therapeutically, anti-CD44 antibodies have been explored to inhibit tumor growth or sensitize cancer cells to chemotherapy. However, challenges remain due to CD44's structural complexity, splice variant diversity, and context-dependent roles. Some antibodies target specific epitopes or isoforms to enhance specificity. For example, antibodies against CD44v6 have been tested in clinical trials for head and neck cancers.
Overall, CD44 antibodies serve as vital tools for understanding cellular mechanisms and developing targeted therapies, though their clinical translation requires careful consideration of isoform specificity and biological context.
×
